Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THEOCLEAR-100 vs AEROLATE JR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Theophylline relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing intracellular c AMP, and antagonizing adenosine receptors.
Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.
Treatment of asthma,Chronic obstructive pulmonary disease (COPD)
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, such as emphysema and chronic bronchitis.
100 mg orally every 6 hours; adjust based on serum theophylline concentrations and clinical response (target 5-15 mcg/m L).
1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.
Terminal elimination half-life is approximately 8-12 hours in healthy adults. In smokers, half-life is reduced by 50%; in patients with hepatic cirrhosis or heart failure, half-life is prolonged to 24-36 hours.
Terminal elimination half-life: 3.5-4.5 hours. This short half-life supports twice-daily dosing in asthma management, with trough levels remaining above therapeutic threshold.
Hepatic via CYP1A2 and CYP3A4; also undergoes N-demethylation and oxidation.
Primarily metabolized in the liver by cytochrome P450 enzymes, including CYP1A2, CYP2E1, and CYP3A4. Metabolism is saturable at high concentrations.
Renal excretion accounts for approximately 10% of the administered dose as unchanged drug. The remainder is hepatically metabolized, with metabolites excreted renally. Biliary/fecal elimination is negligible (<5%).
Renal elimination: 60-70% as unchanged drug and metabolites. Biliary/fecal excretion: 20-30%.
Approximately 40% bound to albumin in plasma.
Approximately 70% bound to plasma proteins, primarily albumin.
Apparent volume of distribution is 0.3-0.65 L/kg, reflecting distribution throughout total body water.
Volume of distribution: 0.3-0.5 L/kg. This moderate Vd indicates distribution into total body water and some tissue binding, but limited by protein binding.
Oral immediate-release: 96-100%. Oral sustained-release: 90-100% relative to immediate-release. Rectal: 80-90%.
Oral bioavailability: Approximately 50% due to first-pass metabolism. Inhalation bioavailability: Variable, with 10-20% reaching systemic circulation; remainder swallowed and undergoes first-pass metabolism.
No specific dose adjustment required for renal impairment; monitor serum levels due to altered pharmacokinetics in severe renal failure (GFR <10 m L/min).
No adjustment required as drug is primarily hepatically metabolized.
Child-Pugh A: reduce dose by 50%; Child-Pugh B: reduce dose by 75%; Child-Pugh C: contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: not recommended.
Initial: 5 mg/kg/day orally divided every 6 hours; titrate based on serum levels. Maximum: 16 mg/kg/day (max 400 mg/day) for children >1 year.
Children 4-11 years: 1 inhalation (35 mcg) twice daily; children 12-17 years: same as adult.
Start at lower end of dosing (e.g., 100 mg every 8-12 hours) due to decreased clearance; monitor serum concentrations closely; target 5-10 mcg/m L.
No specific dose adjustment; initiate at lower end of dosing range due to potential comorbidities.
No FDA black box warning.
None.
Monitor serum levels due to narrow therapeutic index; risk of toxicity (seizures, arrhythmias); use caution in hepatic impairment, heart failure, elderly, and with concurrent medications that alter metabolism.
Concurrent illness (especially with fever), smoking cessation, drug interactions, and hepatic or cardiac impairment can significantly alter theophylline clearance. Serum levels must be monitored due to narrow therapeutic index. Use with caution in patients with peptic ulcer, seizure disorders, or hyperthyroidism.
Hypersensitivity to theophylline; porphyria.
Hypersensitivity to theophylline or any component of the formulation.
High-fat meals may slow absorption of some formulations; charcoal-broiled foods and cruciferous vegetables (e.g., broccoli, cabbage) can increase theophylline clearance. Consistent dietary habits are advised to avoid fluctuations in serum levels.
High-fat meals may delay absorption. Charcoal-broiled foods and high-protein diets can increase clearance. Avoid concurrent consumption of large amounts of caffeine.
FDA Pregnancy Category C. First trimester: limited data suggest possible increased risk of congenital malformations; second and third trimesters: associated with fetal tachycardia, jitteriness, and respiratory distress; avoid use near term due to risk of neonatal theophylline toxicity.
FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used near term due to beta-agonist effects; avoid for tocolysis.
Theophylline excreted into breast milk with infant serum levels approximately 10% of maternal; M/P ratio ~0.7. Cautious use only if benefits outweigh risks; monitor infant for irritability and poor feeding.
Excreted in breast milk; M/P ratio 2.5. Use caution; may cause tremors or tachycardia in infant. Consider risk-benefit.
Increased clearance in second and third trimesters may require dose increases of 30-50%; monitor levels and adjust to maintain therapeutic range; postpartum dose reduction may be needed due to clearance returning to non-pregnant levels.
Pregnancy may reduce plasma concentrations due to increased clearance; consider dose adjustment based on clinical response. Monitor for hypokalemia.
Theophylline has a narrow therapeutic index (5-15 mcg/m L). Monitor serum levels due to variable metabolism; CYP1A2 and CYP3A4 inducers (e.g., smoking, rifampin) decrease levels, while inhibitors (e.g., cimetidine, fluoroquinolones) increase toxicity. Use with caution in heart failure, hepatic impairment, and elderly. Tachyphylaxis may occur with prolonged use.
AEROLATE JR (theophylline) is a bronchodilator used for asthma and COPD. Due to narrow therapeutic index, monitor serum levels (target 5-15 mcg/m L). Caffeine and smoking affect metabolism; smoking cessation may require dose reduction. Avoid in seizure disorders or peptic ulcer.
Take exactly as prescribed; do not double doses.,Report symptoms of toxicity: nausea, vomiting, insomnia, irritability, palpitations, seizures.,Avoid smoking or sudden smoking cessation as it alters drug levels.,Limit caffeine intake (coffee, tea, cola, chocolate) to avoid additive stimulant effects.,Do not crush or chew extended-release tablets; swallow whole.
Take exactly as prescribed; do not change dose without consulting doctor.,Avoid excessive caffeine (coffee, tea, soda, chocolate) as it may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, seizures.,Do not smoke or abruptly stop smoking; notify doctor if smoking habits change.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THEOCLEAR-100 vs AEROLATE JR, answered by our medical review team.
THEOCLEAR-100 is a Bronchodilator that works by Theophylline relaxes bronchial smooth muscle by inhibiting phosphodiesterase, increasing intracellular c AMP, and antagonizing adenosine receptors.. AEROLATE JR is a Bronchodilator that works by Theophylline is a xanthine derivative that acts as a bronchodilator by relaxing bronchial smooth muscle. Its mechanism may involve inhibition of phosphodiesterase, increasing cyclic AMP, and adenosine receptor antagonism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THEOCLEAR-100 and AEROLATE JR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THEOCLEAR-100 is: 100 mg orally every 6 hours; adjust based on serum theophylline concentrations and clinical response (target 5-15 mcg/m L).. The standard adult dose of AEROLATE JR is: 1-2 inhalations (35-50 mcg/inhalation) twice daily via oral inhalation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THEOCLEAR-100 and AEROLATE JR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THEOCLEAR-100 is classified as Category C. FDA Pregnancy Category C. First trimester: limited data suggest possible increased risk of congenital malformations; second and third trimesters: associated with fetal tachycardia,. AEROLATE JR is classified as Category C. FDA Pregnancy Category C. First trimester: No human studies; animal studies show fetal loss, delayed ossification. Second/third trimester: Risk of neonatal hypoglycemia if used nea. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.